If a person's cell have the antigen, the antibody should NOT be present in that person's serum. If an antibody to a blood group antigen is present in the serum of a person, his or her cells should lack that antigen. The antigens are on the cells and the antibodies are in the serum.
Therapy-related myeloid leukemia (t-MDS/t-AML) is a well-recognized clinical syndrome occurring as a late complication following cytotoxic therapy.1â5 The term âtherapy-relatedâ leukemia is descriptive and based on a patientâs history of exposure to cytotoxic agents.
AML patients with these genetic disorders have a better prognosis. Six percent to 8% of patients with AML have structural alterations of 11q23, leading to the MLL rearrangement. The MLL gene rearrangement, also known as mixed lineage leukemia, may lead to AML composed of both myeloid and lymphoid cells. The MLL gene rearrangement portends a worse outcome in patients with AML.